4178 Stock Overview
Operates cord blood cell banks in the United States and Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
StemCyte International, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$26.95 |
| 52 Week High | NT$55.70 |
| 52 Week Low | NT$23.35 |
| Beta | 0 |
| 1 Month Change | -9.87% |
| 3 Month Change | -29.36% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -36.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4178 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -3.1% | 3.0% | 2.3% |
| 1Y | n/a | 1.6% | -1.3% |
Return vs Industry: Insufficient data to determine how 4178 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 4178 performed against the TW Market.
Price Volatility
| 4178 volatility | |
|---|---|
| 4178 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in TW Market | 10.2% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 4178's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: Insufficient data to determine 4178's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | n/a | stemcytebio.com |
StemCyte International, Ltd. operates cord blood cell banks in the United States and Taiwan. It supplies cord blood to medical centers for transplantation in the treatment of blood system diseases; and provides cord blood supply, mononuclear cell supply, and immune cell supply services. The company also develops cord blood to treat COVID-19 syndrome and acute ischemic stroke; and CB201, an immune cell drug.
StemCyte International, Ltd. Fundamentals Summary
| 4178 fundamental statistics | |
|---|---|
| Market cap | NT$5.19b |
| Earnings (TTM) | -NT$205.66m |
| Revenue (TTM) | NT$382.69m |
13.5x
P/S Ratio-25.2x
P/E RatioIs 4178 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4178 income statement (TTM) | |
|---|---|
| Revenue | NT$382.69m |
| Cost of Revenue | NT$264.71m |
| Gross Profit | NT$117.98m |
| Other Expenses | NT$323.64m |
| Earnings | -NT$205.66m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 30.83% |
| Net Profit Margin | -53.74% |
| Debt/Equity Ratio | 0% |
How did 4178 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 12:16 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
StemCyte International, Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.